Profile data is unavailable for this security.
About the company
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
- Revenue in USD (TTM)277.46m
- Net income in USD-52.61m
- Incorporated1989
- Employees275.00
- LocationAmarin Corporation PLCGemini House, Bartholomews WalkDUBLIN FK7 9JQIrelandIRL
- Phone+353 16699020
- Websitehttps://amarincorp.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MeiraGTx Holdings PLC | 11.38m | -74.11m | 258.51m | 402.00 | -- | 2.12 | -- | 22.72 | -1.27 | -1.27 | 0.1887 | 1.89 | 0.0381 | -- | 0.4821 | 27,159.90 | -24.81 | -26.40 | -31.62 | -32.66 | -- | -- | -651.19 | -420.70 | -- | -27.54 | 0.3729 | -- | -11.95 | -- | 35.17 | -- | 12.37 | -- |
| Adaptimmune Therapeutics PLC - ADR | 18.36m | -163.41m | 260.67m | 449.00 | -- | 10.69 | -- | 14.20 | -0.7285 | -0.7285 | 0.0834 | 0.0954 | 0.0672 | -- | 3.63 | 40,886.41 | -59.85 | -41.19 | -78.55 | -48.21 | -- | -- | -890.13 | -714.26 | -- | -- | 0.00 | -- | 122.05 | 0.2595 | 31.18 | -- | 0.7202 | -- |
| MacroGenics Inc | 43.36m | -23.24m | 263.06m | 339.00 | -- | 2.48 | -- | 6.07 | -0.3754 | -0.3754 | 0.6969 | 1.70 | 0.1465 | 5.13 | 2.00 | 127,896.80 | -7.85 | -37.76 | -9.48 | -45.53 | 84.28 | -- | -53.60 | -133.96 | 3.61 | -96.21 | 0.00 | -- | -61.33 | -0.4606 | 92.44 | -- | -41.13 | -- |
| Atea Pharmaceuticals Inc | 0.00 | -163.66m | 276.25m | 74.00 | -- | 0.5477 | -- | -- | -1.96 | -1.96 | 0.00 | 5.99 | 0.00 | -- | -- | 0.00 | -27.48 | -5.90 | -28.78 | -6.98 | -- | -- | -- | -38.91 | -- | -- | 0.00 | -- | -- | -- | -17.30 | -- | -- | -- |
| Inozyme Pharma Inc | 0.00 | -77.11m | 277.73m | 59.00 | -- | 2.34 | -- | -- | -1.37 | -1.37 | 0.00 | 1.92 | 0.00 | -- | -- | 0.00 | -48.39 | -45.00 | -52.50 | -48.90 | -- | -- | -- | -- | -- | -- | 0.2748 | -- | -- | -- | -6.13 | -- | 2.85 | -- |
| Enanta Pharmaceuticals Inc | 72.88m | -131.74m | 278.30m | 145.00 | -- | 1.68 | -- | 3.82 | -6.25 | -6.25 | 3.46 | 7.84 | 0.197 | -- | 5.70 | 502,627.60 | -35.60 | -14.56 | -40.33 | -15.62 | -- | -- | -180.75 | -54.96 | -- | -- | 0.0085 | -- | -8.07 | -17.45 | -9.91 | -- | 24.89 | -- |
| Amarin Corporation plc (ADR) | 277.46m | -52.61m | 282.02m | 275.00 | -- | 0.5164 | -- | 1.02 | -0.1288 | -0.1288 | 0.679 | 1.33 | 0.3363 | 0.4197 | 2.23 | 1,008,927.00 | -6.38 | -4.48 | -8.90 | -6.54 | 63.61 | 75.70 | -18.96 | -8.59 | 1.93 | -- | 0.00 | -- | -16.87 | 6.01 | 44.13 | -- | 55.83 | -- |
| Nautilus Biotechnology Inc | 0.00 | -67.44m | 284.35m | 163.00 | -- | 1.14 | -- | -- | -0.5402 | -0.5402 | 0.00 | 1.99 | 0.00 | -- | -- | 0.00 | -21.26 | -- | -21.85 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.93 | -- | -- | -- |
| Poseida Therapeutics Inc | 82.50m | -108.86m | 285.06m | 335.00 | -- | 3.36 | -- | 3.46 | -1.18 | -1.18 | 0.8907 | 0.8739 | 0.2864 | -- | 8.06 | 250,006.10 | -37.78 | -40.70 | -49.17 | -47.72 | -- | -- | -131.94 | -233.49 | -- | -12.88 | 0.4096 | -- | -50.42 | -- | -92.85 | -- | 19.01 | -- |
| ALX Oncology Holdings Inc | 0.00 | -166.20m | 291.76m | 74.00 | -- | 1.71 | -- | -- | -3.71 | -3.71 | 0.00 | 3.27 | 0.00 | -- | -- | 0.00 | -67.73 | -34.34 | -76.12 | -36.47 | -- | -- | -- | -7,238.76 | -- | -- | 0.067 | -- | -- | -- | -30.23 | -- | 14.30 | -- |
| ADC Therapeutics SA | 68.62m | -227.23m | 294.34m | 273.00 | -- | -- | -- | 4.29 | -2.77 | -2.77 | 0.8368 | -2.35 | 0.1769 | 0.2683 | 2.91 | 251,351.60 | -56.99 | -48.41 | -69.99 | -55.63 | 93.30 | -- | -322.09 | -308.62 | 4.35 | -4.14 | 1.85 | -- | -66.86 | 127.56 | -52.78 | -- | 5.42 | -- |
| XOMA Corp | 5.81m | -45.09m | 301.44m | 13.00 | -- | 3.66 | -- | 51.87 | -3.92 | -3.92 | 0.5053 | 7.08 | 0.0329 | -- | 1,291.33 | 447,000.00 | -22.44 | -4.55 | -24.19 | -4.94 | -- | -- | -681.69 | -31.87 | -- | -24.55 | 0.5944 | -- | -21.06 | -2.13 | -105.10 | -- | 23.16 | -- |
| Agenus Inc | 161.42m | -239.61m | 305.12m | 389.00 | -- | -- | -- | 1.89 | -12.68 | -12.68 | 8.49 | -9.59 | 0.4823 | -- | 170.54 | 414,951.20 | -74.69 | -55.02 | -242.74 | -115.31 | 99.43 | -- | -154.88 | -102.92 | -- | -1.25 | -- | -- | 59.47 | 33.56 | -11.66 | -- | 22.58 | -- |
| Tscan Therapeutics Inc | 14.81m | -96.80m | 309.78m | 161.00 | -- | 2.28 | -- | 20.91 | -1.28 | -1.28 | 0.1784 | 2.57 | 0.0715 | -- | -- | 96,181.82 | -46.72 | -- | -52.48 | -- | -- | -- | -653.50 | -- | -- | -- | 0.1974 | -- | 55.52 | -- | -34.73 | -- | -- | -- |
Data as of Jul 03 2024. Currency figures normalised to Amarin Corporation PLC's reporting currency: US Dollar USD
16.14%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Sarissa Capital Management LPas of 31 Mar 2024 | 24.85m | 6.05% |
| Kynam Capital Management LPas of 31 Mar 2024 | 12.02m | 2.93% |
| DG Capital Management LLCas of 31 Mar 2024 | 6.44m | 1.57% |
| Eversept Partners LPas of 31 Mar 2024 | 6.21m | 1.51% |
| Two Sigma Investments LPas of 31 Mar 2024 | 3.39m | 0.83% |
| Morgan Stanley & Co. LLCas of 31 Mar 2024 | 3.21m | 0.78% |
| Two Sigma Advisers LPas of 31 Mar 2024 | 2.81m | 0.68% |
| SCP Investment LPas of 31 Mar 2024 | 2.50m | 0.61% |
| Tang Capital Management LLCas of 31 Mar 2024 | 2.50m | 0.61% |
| MFP Investors LLCas of 31 Mar 2024 | 2.38m | 0.58% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
